Antoine Thiery-Vuillemin

机构：Inserm, Bristol-Myers Squibb (Germany), Centre Hospitalier Universitaire de Besançon, Bristol-Myers Squibb (France), Bristol-Myers Squibb (Switzerland) · ORCID：0000-0001-6822-3401

发表论文 311 篇 · 总被引 10491 次 · h-index 35

代表论文

• Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial (2023 · Journal of Clinical Oncology · 被引 97)
• Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance (2023 · European Urology · 被引 25)
• Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma (2023 · The Oncologist · 被引 23)
• Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer (2023 · JAMA Oncology · 被引 21)
• rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC (2025 · Future Oncology · 被引 12)
• Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study (2024 · European Journal of Cancer · 被引 8)